Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase

被引:48
作者
Learmonth, DA
Vieira-Coelho, MA
Benes, J
Alves, PC
Borges, N
Freitas, AP
Soares-Da-Silva, P [1 ]
机构
[1] BIAL, Dept Res & Dev, Pharmacol Lab, P-4745457 S Mamede Do Coronado, Portugal
[2] BIAL, Dept Res & Dev, Chem Lab, P-4745457 S Mamede Do Coronado, Portugal
关键词
D O I
10.1021/jm0109964
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A homologous series of novel nitro-catechol structures (7a-7e) were synthesized and tested as inhibitors of the enzyme catechol-O-methyltransferase (COMT). Increasing chain length was found to have significant impact on both brain penetration and duration of COMT inhibition in the rat. Of this series, compound 7b (1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone) was found to exhibit the most potent and selective inhibition of peripheral COMT, with an inhibition profile more similar to entacapone 2 than tolcapone 1 (an equipotent peripheral and central inhibitor) but with much improved duration of action (7b, 70% inhibition and 2, 25% inhibition at 9 h after administration). The effects of structural modifications to 7b on COMT inhibitory profile were investigated, and it is concluded that the carbonyl group and preferably unsubstituted aromatic ring are essential features to maintain prolonged peripheral COMT inhibition. The introduction of the alpha-methylene group, the major structural difference between 7b and 1, would appear responsible for the observed enhancement in selectivity of peripheral COMT inhibition of 7b, which has more limited access to the brain than 1.
引用
收藏
页码:685 / 695
页数:11
相关论文
共 37 条
  • [1] Tolcapone and fulminant hepatitis
    Assal, F
    Spahr, L
    Hadengue, A
    Rubbici-Brandt, L
    Burkhard, PR
    [J]. LANCET, 1998, 352 (9132) : 958 - 958
  • [2] AXELROD J, 1958, J BIOL CHEM, V233, P702
  • [3] AXELROD J, 1958, J BIOL CHEM, V233, P697
  • [4] SYNTHESIS OF SOME NOVEL POTENT AND SELECTIVE CATECHOL O-METHYLTRANSFERASE INHIBITORS
    BACKSTROM, R
    HONKANEN, E
    PIPPURI, A
    KAIRISALO, P
    PYSTYNEN, J
    HEINOLA, K
    NISSINEN, E
    LINDEN, IB
    MANNISTO, PT
    KAAKKOLA, S
    POHTO, P
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (04) : 841 - 846
  • [5] DECARBOXYLASE INHIBITORS
    BARTHOLINI, G
    PLETSCHER, A
    [J]. PHARMACOLOGY & THERAPEUTICS PART B-GENERAL & SYSTEMATIC PHARMACOLOGY, 1975, 1 (03): : 407 - 421
  • [6] New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease
    Bonifati, V
    Meco, G
    [J]. PHARMACOLOGY & THERAPEUTICS, 1999, 81 (01) : 1 - 36
  • [7] AFFINITY LABELING OF CATECHOL O-METHYLTRANSFERASE BY N-HALOACETYL DERIVATIVES OF 3,5-DIMETHOXY-4-HYDROXYPHENYLETHYLAMINE AND 3,4-DIMETHOXY-5-HYDROXYPHENYLETHYLAMINE - KINETICS OF INACTIVATION
    BORCHARDT, RT
    THAKKER, DR
    [J]. BIOCHEMISTRY, 1975, 14 (20) : 4543 - 4551
  • [8] Borges N, 1997, J PHARMACOL EXP THER, V282, P812
  • [9] CATECHOL-O-METHYLTRANSFERASE-INHIBITING PYROCATECHOL DERIVATIVES - SYNTHESIS AND STRUCTURE-ACTIVITY STUDIES
    BORGULYA, J
    BRUDERER, H
    BERNAUER, K
    ZURCHER, G
    DAPRADA, M
    [J]. HELVETICA CHIMICA ACTA, 1989, 72 (05) : 952 - 968
  • [10] BORGULYA J, 1991, Drugs of the Future, V16, P719